Key Highlights
- Harmony Biosciences reports record Q2 WAKIX revenue of approximately $261 million, up 30% year-over-year.
- HRMY misses Q1 EPS estimate, reporting a lower-than-expected result for the quarter.
- Glenn Reicin steps down as CFO; Stephen Mollichella named interim principal financial officer.
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) delivered a mixed quarterly update, posting record revenue for its narcolepsy drug WAKIX while missing earnings estimates and announcing the departure of its chief financial officer. The company reported preliminary Q2 net product revenue of approximately $261 million, a 30% year-over-year increase, but first-quarter earnings per share fell short of expectations. Harmony’s Q1 earnings miss marks a rare setback for the biopharmaceutical firm, which has otherwise demonstrated consistent growth in its WAKIX franchise.
The company’s revenue momentum, however, remains intact, with Q2 WAKIX sales climbing year-over-year, signaling sustained demand for its narcolepsy treatment. The departure of Glenn Reicin, who stepped down as CFO, adds a layer of operational uncertainty. Reicin’s exit follows the company’s recent leadership changes.
Mollichella, who joined the company in 2021, brings two decades of finance leadership experience in biopharma and medical technology, having overseen Harmony’s financial reporting, controls, and business development initiatives. The transition is not expected to disrupt financial operations, though investors may monitor the search for a permanent successor closely. With a market capitalization and shares trading near the lower end of their 52-week range, the company faces pressure to demonstrate margin resilience alongside revenue growth.
The year-to-date decline contrasts with WAKIX’s strong commercial performance, suggesting that profitability concerns may be weighing on sentiment more than top-line trends. Investors will look to Harmony’s full Q2 financial results and business update for clarity on gross margins, operating expenses, and any adjustments to guidance. The earnings call will also provide an opportunity to assess the interim CFO’s strategic priorities and the timeline for a permanent hire.
Investor Insights
With WAKIX’s growth trajectory intact, the company’s ability to stabilize earnings and communicate a clear financial roadmap will be critical in reversing recent share price weakness.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...